摘要
目的分析地诺前列酮栓联合利凡诺用于瘢痕子宫引产的临床疗效。方法选取河北港口集团有限公司港口医院和昌黎县妇幼保健院2020年2月至2022年2月期间收治的妊娠中期瘢痕子宫终止妊娠患者98例作为研究对象,按照引产方案分为对照组(利凡诺治疗)和研究组(利凡诺+地诺前列酮栓治疗),每组49例。比较两组围术期指标、用药后宫颈成熟度、引产成功率、不良反应及术后并发症差异。结果与对照组比较,研究组宫缩发动时间、胎儿娩出时间以及住院时间明显缩短(P<0.05);研究组引产出血量、引产2 h出血量明显少于对照组(P<0.05);用药后6 h、12 h、18 h,研究组宫颈成熟度Bishop评分均高于对照组(P<0.05);研究组完全引产率(95.92%)明显高于对照组(87.76%,P<0.05)。结论地诺前列酮栓联合利凡诺用于中期妊娠瘢痕子宫引产,具备良好引产结局,具有临床推广潜力。
Objective Analyze the clinical efficacy of the combination of denoprorelin suppositories and rivanol for induced labor in scarred uterus.Methods A total of 98 patients with scarred uterus in the second trimester of pregnancy who were admitted to Port Hospital of Hebei Port Group Co.,Ltd.and Changli County Maternal and Child Health Hospital from February 2020 to February 2022 were selected as the research objects.According to the induction protocol,they were divided into the control group(rivanol treatment)and the study group(rivanol+desoprostone suppository treatment),with 49 cases in each group.The perioperative indicators,cervical maturity,success rate of induced labor,adverse reactions and postoperative complications were compared between the two groups.Results Compared with the control group,the time of uterine contraction initiation,fetal delivery and hospital stay in the study group were significantly shortened(P<0.05).The blood loss during labor induction and 2 h after labor induction in the study group was significantly lower than that in the control group(P<0.05).Bishop score of cervical maturity in study group was higher than that in control group at 6 h,12 h and 18 h after treatment(P<0.05).The total induced labor rate of the study group(95.92%)was significantly higher than that of the control group(87.76%,P<0.05).Conclusion Dinoprostione suppository combined with rivanol for inducing labor in scarred uterus of second trimester has good outcome and has clinical promotion potential.
作者
孙丹华
邓丽娜
韩晶晶
鞠秀丽
刘国芳
董文
SUN Danhua;DENG Li'na;HAN Jingjing;JU Xiuli;LIU Guofang;DONG Wen(Department of Obstetrics and Gynecology,Port Hospital,Hebei Port Group Co.,LTD.,Qinhuangdao 066000,Hebei province,China)
出处
《世界临床药物》
CAS
2024年第10期1067-1071,共5页
World Clinical Drug
基金
秦皇岛市科学技术研究与发展计划(202004A109)。
关键词
瘢痕子宫
地诺前列酮栓
利凡诺
中期妊娠
终止妊娠
scared uterus
dinoprostone suppository
rivanol
second trimester pregnancy
terminal pregnancy